Repository logo
 
Publication

ATTR amyloidosis during the COVID-19 pandemic: insights from a global medical roundtable

2021-05Journal article Open access
Simple item page
dc.contributor.authorBrannagan, Thomas H.
dc.contributor.authorAuer-Grumbach, Michaela
dc.contributor.authorBerk, John L.
dc.contributor.authorBriani, Chiara
dc.contributor.authorBril, Vera
dc.contributor.authorCoelho, Teresa
dc.contributor.authorDamy, Thibaud
dc.contributor.authorDispenzieri, Angela
dc.contributor.authorDrachman, Brian M.
dc.contributor.authorFine, Nowell
dc.contributor.authorGaggin, Hanna K.
dc.contributor.authorGertz, Morie
dc.contributor.authorGillmore, Julian D.
dc.contributor.authorGonzalez, Esther
dc.contributor.authorHanna, Mazen
dc.contributor.authorHurwitz, David R.
dc.contributor.authorKhella, Sami L.
dc.contributor.authorMaurer, Mathew S.
dc.contributor.authorNativi-Nicolau, Jose
dc.contributor.authorOlugemo, Kemi
dc.contributor.authorQuintana, Luis F.
dc.contributor.authorRosen, Andrew M.
dc.contributor.authorSchmidt, Hartmut H.
dc.contributor.authorShehata, Jacqueline
dc.contributor.authorWaddington-Cruz, Marcia
dc.contributor.authorWhelan, Carol
dc.contributor.authorRuberg, Frederick L.
dc.date.accessioned2023-10-30T15:47:18Z
dc.date.available2023-10-30T15:47:18Z
dc.date.issued2021-05
dc.description.abstractBackground: The global spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection causing the ongoing coronavirus disease 2019 (COVID-19) pandemic has raised serious concern for patients with chronic disease. A correlation has been identified between the severity of COVID-19 and a patient's preexisting comorbidities. Although COVID-19 primarily involves the respiratory system, dysfunction in multiple organ systems is common, particularly in the cardiovascular, gastrointestinal, immune, renal, and nervous systems. Patients with amyloid transthyretin (ATTR) amyloidosis represent a population particularly vulnerable to COVID-19 morbidity due to the multisystem nature of ATTR amyloidosis. Main body: ATTR amyloidosis is a clinically heterogeneous progressive disease, resulting from the accumulation of amyloid fibrils in various organs and tissues. Amyloid deposition causes multisystem clinical manifestations, including cardiomyopathy and polyneuropathy, along with gastrointestinal symptoms and renal dysfunction. Given the potential for exacerbation of organ dysfunction, physicians note possible unique challenges in the management of patients with ATTR amyloidosis who develop multiorgan complications from COVID-19. While the interplay between COVID-19 and ATTR amyloidosis is still being evaluated, physicians should consider that the heightened susceptibility of patients with ATTR amyloidosis to multiorgan complications might increase their risk for poor outcomes with COVID-19. Conclusion: Patients with ATTR amyloidosis are suspected to have a higher risk of morbidity and mortality due to age and underlying ATTR amyloidosis-related organ dysfunction. While further research is needed to characterize this risk and management implications, ATTR amyloidosis patients might require specialized management if they develop COVID-19. The risks of delaying diagnosis or interrupting treatment for patients with ATTR amyloidosis should be balanced with the risk of exposure in the health care setting. Both physicians and patients must adapt to a new construct for care during and possibly after the pandemic to ensure optimal health for patients with ATTR amyloidosis, minimizing treatment interruptions.pt_PT
dc.description.sponsorshipMedical writing assistance was funded by Akcea Therapeuticspt_PT
dc.description.versioninfo:eu-repo/semantics/publishedVersionpt_PT
dc.identifier.citationBrannagan TH 3rd, Auer-Grumbach M, Berk JL, et al. ATTR amyloidosis during the COVID-19 pandemic: insights from a global medical roundtable. Orphanet J Rare Dis. 2021;16(1):204. doi:10.1186/s13023-021-01834-0pt_PT
dc.identifier.doi10.1186/s13023-021-01834-0pt_PT
dc.identifier.issn1750-1172
dc.identifier.urihttp://hdl.handle.net/10400.16/2859
dc.language.isoengpt_PT
dc.peerreviewedyespt_PT
dc.publisherBioMed Centralpt_PT
dc.relation.publisherversionhttps://ojrd.biomedcentral.com/articles/10.1186/s13023-021-01834-0pt_PT
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/pt_PT
dc.subjectATTRpt_PT
dc.subjectAmyloidosispt_PT
dc.subjectCOVID-19pt_PT
dc.subjectRare diseasept_PT
dc.subjectSARS-CoV-2pt_PT
dc.titleATTR amyloidosis during the COVID-19 pandemic: insights from a global medical roundtablept_PT
dc.typejournal article
dspace.entity.typePublication
oaire.citation.conferencePlaceEnglandpt_PT
oaire.citation.issue1pt_PT
oaire.citation.startPage204pt_PT
oaire.citation.titleOrphanet Journal of Rare Diseasespt_PT
oaire.citation.volume16pt_PT
person.familyNameCoelho
person.givenNameTeresa
person.identifier.ciencia-idC71E-3343-F445
rcaap.rightsopenAccesspt_PT
rcaap.typearticlept_PT
relation.isAuthorOfPublicationca69c0a3-d48a-4b92-bbf7-c17288d609b7
relation.isAuthorOfPublication.latestForDiscoveryca69c0a3-d48a-4b92-bbf7-c17288d609b7

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Brannagan-2021-Attr-amyloidosis-during-the-covid--.pdf
Size:
1.15 MB
Format:
Adobe Portable Document Format
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.44 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

SNF - Artigos publicados em revistas indexadas na Pubmed/Medline